Although PPARα agonists are used in clinic to treat mixed dyslipidemia and hypertriglyceridemia, few studies have investigated the outcomes of these treatments for NAFLD. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.